| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Biocept Inc (NASDAQ: BIOC)
BIOC Technical Analysis
5
| As on 26th Dec 2023 BIOC STOCK Price closed @ 0.07 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.86 & Strong Sell for SHORT-TERM with Stoploss of 1.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BIOCSTOCK Price
| Open | 0.03 | Change | Price | % |
| High | 0.07 | 1 Day | 0.04 | 133.33 |
| Low | 0.03 | 1 Week | -0.02 | -22.22 |
| Close | 0.07 | 1 Month | -0.13 | -65.00 |
| Volume | 65116 | 1 Year | -0.96 | -93.20 |
| 52 Week High 6.65 | 52 Week Low 0.03 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| NVDA | 146.67 | 0.53% |
| AKTS | 0.10 | 11.11% |
| WORX | 2.12 | 116.33% |
| QUBT | 4.76 | 29.35% |
| LMDX | 0.02 | 0.00% |
| SMCI | 29.70 | 5.06% |
| MSTR | 397.28 | -16.16% |
| MARA | 23.81 | 22.17% |
| CRNC | 5.83 | 106.74% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BIOC Daily Charts |
BIOC Intraday Charts |
Whats New @ Bazaartrend |
BIOC Free Analysis |
|
|
BIOC Important Levels Intraday
| RESISTANCE | 0.15 |
| RESISTANCE | 0.12 |
| RESISTANCE | 0.11 |
| RESISTANCE | 0.09 |
| SUPPORT | 0.05 |
| SUPPORT | 0.03 |
| SUPPORT | 0.02 |
| SUPPORT | -0.01 |
BIOC Forecast November 2024
| 4th UP Forecast | 0.86 |
| 3rd UP Forecast | 0.61 |
| 2nd UP Forecast | 0.45 |
| 1st UP Forecast | 0.29 |
| 1st DOWN Forecast | -0.15 |
| 2nd DOWN Forecast | -0.31 |
| 3rd DOWN Forecast | -0.47 |
| 4th DOWN Forecast | -0.72 |
BIOC Weekly Forecast
| 4th UP Forecast | 0.40 |
| 3rd UP Forecast | 0.29 |
| 2nd UP Forecast | 0.23 |
| 1st UP Forecast | 0.16 |
| 1st DOWN Forecast | -0.02 |
| 2nd DOWN Forecast | -0.09 |
| 3rd DOWN Forecast | -0.15 |
| 4th DOWN Forecast | -0.26 |
BIOC Forecast2024
| 4th UP Forecast | 25.89 |
| 3rd UP Forecast | 17.61 |
| 2nd UP Forecast | 12.49 |
| 1st UP Forecast | 7.37 |
| 1st DOWN Forecast | -7.23 |
| 2nd DOWN Forecast | -12.35 |
| 3rd DOWN Forecast | -17.47 |
| 4th DOWN Forecast | -25.75 |
Biocept Inc ( NASDAQ USA Symbol : BIOC )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BIOC Business Profile
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California. Address: 9955 Mesa Rim Road, San Diego, CA, United States, 92121
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service